As we continue in this exciting period of growth at entX, I would like to thank our shareholders, partners and broader community for their ongoing support and engagement.

Over recent weeks, we have continued building momentum across our healthcare, space and defence initiatives, highlighted by several important milestones. One of the most significant developments has been our recently announced agreement with Telix Pharmaceuticals, representing a major step forward for our radioisotope supply and processing capabilities. The agreement marks an important milestone in entX’s strategy to build sovereign Australian manufacturing capability across the radiopharmaceutical supply chain while strengthening partnerships within the global nuclear medicine sector. Read more.

Importantly, significant opportunities have opened up for entX as the race to return to the lunar surface accelerates. The US Government has announced a significant expansion of its lunar exploration plans, with its Ignition program releasing the CS-8 mission, which calls for CLPS (Commercial Lunar Payload Services) providers to design and deliver lunar payloads capable of surviving the lunar night. Up to three contract performance bonuses of USD15 million each will be awarded to CLPS providers that successfully demonstrate “survive the night” capability by transmitting 1 bit of data after the lunar night using a radioisotope device. During a recent trip to the US, entX engaged with several CLPS providers and proposed a thermal management solution consisting of our RHU and Thermal Switch. We expect to be notified in Q3.

We also recently concluded our four-part investor webinar series, providing further insight into entX’s strategy, technologies and commercial opportunities. Across the series, we explored the progress of IsoMedica, GenX and our Radioisotope Heating Unit (RHU) initiatives, while highlighting how entX is positioning itself across healthcare innovation, sovereign capability, and advanced power systems for future space and defence applications. Thank you to everyone who joined the sessions and engaged with our team throughout the series.

On Friday, 22 May, we held our Annual General Meeting. All resolutions put to shareholders were passed, including the election of Dr Gabriel Liberatore, who was appointed to the Board in February 2026. We are pleased to welcome Dr Liberatore to the team. An experienced executive in the pharmaceutical and biotechnology sectors, Dr Liberatore brings valuable expertise as entX enters its next phase of growth and commercial development.

On behalf of the Board and leadership team, thank you again for your continued confidence in entX. We remain focused on executing our strategy, advancing our technologies and creating long-term value as we continue building a globally relevant Australian innovation company.

Warm regards,

Bryn Jones

Managing Director